Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Shares Issued (2016 - 2025)

Dexcom (DXCM) has disclosed Shares Issued for 16 consecutive years, with $13.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued fell 6.08% to $13.9 million in Q3 2025 year-over-year; TTM through Dec 2025 was $28.1 million, a 0.35% change, with the full-year FY2025 number at $28.1 million, changed 0.35% from a year prior.
  • Shares Issued was $13.9 million for Q3 2025 at Dexcom, down from $14.2 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $14.8 million in Q3 2024 to a low of $8.7 million in Q1 2021.
  • A 5-year average of $12.6 million and a median of $12.9 million in 2022 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: surged 34.88% in 2021, then decreased 6.08% in 2025.
  • Dexcom's Shares Issued stood at $11.6 million in 2021, then increased by 6.9% to $12.4 million in 2022, then rose by 15.32% to $14.3 million in 2023, then rose by 3.5% to $14.8 million in 2024, then fell by 6.08% to $13.9 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Shares Issued are $13.9 million (Q3 2025), $14.2 million (Q1 2025), and $14.8 million (Q3 2024).